G Zheng

First name:
G
Last name:
Zheng
Smith, A. M., Pivavarchyk, M., Wooters, T. E., Zhang, Z., Zheng, G., McIntosh, J. M., et al. (2010). Repeated nicotine administration robustly increases bPiDDB inhibitory potency at alpha6beta2-containing nicotinic receptors mediating nicotine-evoked dopamine release. Biochemical Pharmacology, 80(3), 402-9. https://doi.org/10.1016/j.bcp.2010.03.018 (Original work published 2010)
View
Zhao, N., Zheng, G., Li, J., Zhao, H. Y., Lu, C., Jiang, M., et al. (2018). Text mining of rheumatoid arthritis and diabetes mellitus to understand the mechanisms of Chinese medicine in different diseases with same treatment. Chinese Journal Of Integrative Medicine. https://doi.org/10.1007/s11655-018-2825-x (Original work published 2018)
View
Pan, Z., Chen, M., Zhang, Q., Wang, E., Yin, L., Xu, Y., et al. (2018). CD3-positive plasmablastic B-cell neoplasms: a diagnostic pitfall. Modern Pathology : An Official Journal Of The United States And Canadian Academy Of Pathology, Inc. https://doi.org/10.1038/modpathol.2017.177 (Original work published 2018)
View
Beckmann, J. S., Meyer, A. C., Pivavarchyk, M., Horton, D. B., Zheng, G., Smith, A. M., et al. (2015). r-bPiDI, an α6β2* Nicotinic Receptor Antagonist, Decreases Nicotine-Evoked Dopamine Release and Nicotine Reinforcement. Neurochemical Research, 40(10), 2121-30. https://doi.org/10.1007/s11064-015-1680-4
View
Wilmouth, C. E., Zheng, G., Crooks, P. A., Dwoskin, L. P., & Bardo, M. T. (2013). Oral administration of GZ-793A, a VMAT2 inhibitor, decreases methamphetamine self-administration in rats. Pharmacology, Biochemistry, And Behavior, 112, 29-33. https://doi.org/10.1016/j.pbb.2013.09.006
View
Meyer, A. C., Neugebauer, N. M., Zheng, G., Crooks, P. A., Dwoskin, L. P., & Bardo, M. T. (2013). Effects of VMAT2 inhibitors lobeline and GZ-793A on methamphetamine-induced changes in dopamine release, metabolism and synthesis in vivo. Journal Of Neurochemistry, 127(2), 187-98. https://doi.org/10.1111/jnc.12373
View
Dwoskin, L. P., Joyce, B. M., Zheng, G., Neugebauer, N. M., Manda, V. K., Lockman, P., et al. (2007). Discovery of a novel nicotinic receptor antagonist for the treatment of nicotine addiction: 1-(3-Picolinium)-12-triethylammonium-dodecane dibromide (TMPD). Biochemical Pharmacology, 74(8), 1271-82. https://doi.org/10.1016/j.bcp.2007.07.021 (Original work published 2007)
View
Dwoskin, L. P., Pivavarchyk, M., Joyce, B. M., Neugebauer, N. M., Zheng, G., Zhang, Z., et al. Targeting reward-relevant nicotinic receptors in the discovery of novel pharmacotherapeutic agents to treat tobacco dependence. Nebraska Symposium On Motivation. Nebraska Symposium On Motivation, 55, 31-63. https://doi.org/10.1007/978-0-387-78748-0_4 (Original work published 2009)
View
Alvers, K. M., Beckmann, J. S., Zheng, G., Crooks, P. A., Dwoskin, L. P., & Bardo, M. T. (2012). The effect of VMAT2 inhibitor GZ-793A on the reinstatement of methamphetamine-seeking in rats. Psychopharmacology, 224(2), 255-62. https://doi.org/10.1007/s00213-012-2748-3
View
Beckmann, J. S., Denehy, E. D., Zheng, G., Crooks, P. A., Dwoskin, L. P., & Bardo, M. T. (2012). The effect of a novel VMAT2 inhibitor, GZ-793A, on methamphetamine reward in rats. Psychopharmacology, 220(2), 395-403. https://doi.org/10.1007/s00213-011-2488-9
View